ArticlemSphere2018
Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 35 citations in OpenAlex.
- Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children.The Journal of infectious diseases · 2021Trial
- Antibodies Elicited by theFrontiers in immunology · 2021Trial
- Protective immunity againstmSphere · 2026Article
- Development of an 8-valentFrontiers in immunology · 2026Article
- Development and evaluation of a dual-target glycoconjugate againstFrontiers in immunology · 2026Article
- Determinants of immune responses predictive of protection against shigellosis in an endemic zone: a systems analysis of antibody profiles and function.The Lancet. Microbe · 2024Article
- Evaluation of a QuadrivalentVaccines · 2024Article
- Investigation of the vaccine potential of anVaccine: X · 2024Article
- Oral immunization withmSphere · 2024Article
- Review
- A next-generation GMMA-based vaccine candidate to fight shigellosis.NPJ vaccines · 2023Article
- Article
- A NovelmSphere · 2023Article
- Article
- Toward aInternational journal of molecular sciences · 2023Review
- Functional assays to evaluate antibody-mediated responses againstFrontiers in cellular and infection microbiology · 2023Review
- Development and Characterization of a Luminescence-Based High-Throughput Serum Bactericidal Assay (L-SBA) to Assess Bactericidal Activity of Human Sera against NontyphoidalMethods and protocols · 2022Article
- TheVaccines · 2022Review
- Systems approach to define humoral correlates of immunity to Shigella.Cell reports · 2022Article
- Setup and Characterization of a High-Throughput Luminescence-Based Serum Bactericidal Assay (L-SBA) to Determine Functionality of Human Sera againstBiotech (Basel (Switzerland)) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.